Advances in immunotyping of colorectal cancer

Frontiers in Immunology

Immunology

Shuwen Han¹  Yinhang Wu¹  Jing Zhuang¹  Zhanbo Qu¹  Xi Yang¹ 

[1] Huzhou Central Hospital, Affiliated Central Hospital HuZhou University, Huzhou, China;Key Laboratory of Multiomics Research and Clinical Transformation of Digestive Cancer of Huzhou, Huzhou, China;Huzhou Central Hospital, Fifth Affiliated Clinical Medical College of Zhejiang Chinese Medical University, Huzhou, China;

关键词: colorectal cancer;    immunotherapy;    immune subtype;    tumor immune microenvironment;    colorectal cancer subtypes;   

DOI  :  10.3389/fimmu.2023.1259461

 received in 2023-07-17, accepted in 2023-09-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immunotherapy has transformed treatment for various types of malignancy. However, the benefit of immunotherapy is limited to a minority of patients with mismatch-repair-deficient (dMMR) and microsatellite instability-high (MSI-H) (dMMR-MSI-H) colorectal cancer (CRC). Understanding the complexity and heterogeneity of the tumor immune microenvironment (TIME) and identifying immune-related CRC subtypes will improve antitumor immunotherapy. Here, we review the current status of immunotherapy and typing schemes for CRC. Immune subtypes have been identified based on TIME and prognostic gene signatures that can both partially explain clinical responses to immune checkpoint inhibitors and the prognosis of patients with CRC. Identifying immune subtypes will improve understanding of complex CRC tumor heterogeneity and refine current immunotherapeutic strategies.

【 授权许可】

Unknown   
Copyright © 2023 Wu, Zhuang, Qu, Yang and Han